因涉外销售订单收入确认不审慎 迪瑞医疗及3名高管被出具警示函

Core Viewpoint - The company, Dirui Medical Technology Co., Ltd., has received administrative regulatory measures from the Jilin Securities Regulatory Bureau due to issues related to the recognition of foreign sales order revenues and inadequate internal controls, leading to corrective actions and warnings issued to three responsible individuals [1][2][3] Group 1: Regulatory Issues - The company was found to have recognized revenue from foreign sales orders without proper prudence, resulting in an overstatement of operating revenue by 3.693 million yuan and operating profit by 716,000 yuan for the year 2023 [1][3] - Inadequate internal controls were identified, with incomplete documentation related to some foreign sales orders [2][3] Group 2: Consequences and Company Profile - The overstatement of operating revenue of 3.693 million yuan represents 0.27% of the company's total operating revenue for 2023 [3] - The Jilin Securities Regulatory Bureau has mandated corrective actions and recorded the penalties in the securities and futures market integrity archives for the company and the responsible individuals [3] - Dirui Medical specializes in the research, production, marketing, and service of medical testing instruments and related reagents, having entered the capital market in 2014 [3] - As of February 9, 2026, the company's stock price was 13.34 yuan, with a total market value of 3.638 billion yuan, reflecting a cumulative decline of 15.99% in stock price over the past year [3]